已收盤 12-12 16:00:00 美东时间
-0.001
-6.97%
- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne -- Dermata expects to launch a new once-weekly, Over-the-Counter (OTC)
10-02 20:02
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced a bold strategic pivot to prioritize the development and
09-10 20:09
- About 550 patients will be treated once weekly for 12 weeks -- STAR-1 topline results expected in first quarter of 2025 -- Acne affects about 50 million patients in the U.S. -SAN DIEGO, CA / ACCESSWIRE / December 20,
2023-12-21 05:09
SAN DIEGO, CA / ACCESSWIRE / August 31, 2023 / Dermata Therapeutics, Inc. (Nasd...
2023-08-31 09:00
SAN DIEGO, CA / ACCESSWIRE / August 17, 2021 / Dermata Therapeutics, Inc. ("Der...
2021-08-18 09:21